Status:
COMPLETED
A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease
Lead Sponsor:
Pfizer
Conditions:
Dry Eye Syndromes
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.
Eligibility Criteria
Inclusion
- Subjective symptoms of dry eye for at least 6 months
- Signs of moderate to severe dry eye (corneal staining score and schirmer test without anesthesia)
Exclusion
- Women who are nursing, pregnant or planning pregnancy during the study
- Participation in other studies within 30 days of screening visit
- Ocular disorders that may confound interpretation of study results
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
285 Patients enrolled
Trial Details
Trial ID
NCT01135511
Start Date
July 1 2010
End Date
April 1 2011
Last Update
May 7 2013
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ichinomiya, Aichi-ken, Japan
2
Pfizer Investigational Site
Narashino, Chiba, Japan
3
Pfizer Investigational Site
Urayasu, Chiba, Japan
4
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan